<DOC>
	<DOCNO>NCT01777061</DOCNO>
	<brief_summary>When evaluate prostate cancer patient recurrent disease , compute tomography ( CT ) , magnetic resonance imaging ( MRI ) highly sensitive method detect lymph node , specific whether lymph node malignant benign . While positron emission tomography ( PET ) utilize radioactive glucose ( FDG ) revolutionize staging , restaging , monitor response therapy many prevalent cancer breast , colorectal , esophageal , head neck , lung , lymphoma , melanoma , finding prostate cancer proven less sensitive prostate cancer low avidity glucose . A new PET isotope , utilize acetate incorporate cell membrane rapidly proliferate cell , show great sensitivity FDG detect prostate cancer . This study assess clinical effectiveness utilize [ 11C ] Acetate PET scan identifying recurrent prostate cancer .</brief_summary>
	<brief_title>Clinical Management Decisions Recurrent Prostate Cancer Patients Based 11CAcetate PET Scan</brief_title>
	<detailed_description>FDG-PET imaging use form radioactive glucose ( 18-fluoro-deoxyglucose FDG ) , allow measurement glucose metabolic rate tissue body . The prevalent tumor glucose avidity typically great 2.5 time avidity benign tissue . Therefore , FDG-PET able discriminate benign lymph node contain metastasis , similarly scar tissue recurrence tumor . Unfortunately , prostate cancer minimally glucose avid , therefore , FDG-PET much less effective stag prostate cancer . The current FDA-approved imaging agent prostate cancer monoclonal antibody specific prostate cancer cell , capromab pendetide , label long-lived radionuclide [ 111 ] Indium use image patient six day period . However , recent data show another PET radiopharmaceutical , [ 11C ] Acetate ( FDA approve year cardiac imaging ) , avidly take prostate metastasis sensitive either [ 111 ] Indium capromab pendetide FDG-PET . This study assess clinical effectiveness utilize [ 11C ] Acetate PET scan identifying recurrent prostate cancer aim find PSA level effective .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Positive recurrent prostate cancer PSA criterion Recurrence definition : Status postoperative radical prostatectomy , recurrence define PSA great equal 0.2 ng/ml Patients fail external beam radiation , status postbrachytherapy , recurrence define PSA 2.0 ng/ml nadir PSA treatment Subject able comprehend study objective provide write informed consent initiation studyrelated procedure . Eastern Cooperative Oncology Group ( ECOG ) status â‰¥ 2 Any concurrent malignancy Patients without remission disease ( PSA decrease ) Patients without recurrence disease ( PSA remain low )</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Recurrent Prostate Cancer</keyword>
	<keyword>PET Scan</keyword>
	<keyword>FDG-PET</keyword>
	<keyword>[ 11C ] Acetate</keyword>
	<keyword>C11-Acetate</keyword>
</DOC>